Company

TaiGen Biopharmaceuticals Holdings Ltd

Headquarters: Taipei, Taiwan

CEO: Dr. Ming-Chu Hsu

TWSE: 4157 -6.87%

Market Cap

TW$10.95 Billion

TWD as of July 1, 2024

US$336.3 Million

Market Cap History

TaiGen Biopharmaceuticals Holdings Ltd Categories

Taiwan Healthcare Biotechnology
Taiwan Healthcare Taiwan Biotechnology

TaiGen Biopharmaceuticals Holdings Ltd market capitalization over time

Evolution of TaiGen Biopharmaceuticals Holdings Ltd market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of TaiGen Biopharmaceuticals Holdings Ltd

Detailed Description

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for infectious diseases and other indications worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

TaiGen Biopharmaceuticals Holdings Ltd has the following listings and related stock indices.


Stock: TWSE: 4157 wb_incandescent

Details

Headquarters:

No. 138, Xinming Road

7th Floor Neihu District

Taipei, 11470

Taiwan

Phone: 886 2 8177 7020

Fax: 886 2 2796 3606